213 related articles for article (PubMed ID: 23722471)
1. A personalised approach to prostate cancer screening based on genotyping of risk founder alleles.
Cybulski C; Wokołorczyk D; Kluźniak W; Kashyap A; Gołąb A; Słojewski M; Sikorski A; Puszyński M; Soczawa M; Borkowski T; Borkowski A; Antczak A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Domagała P; Piotrowski K; Menkiszak J; Krzystolik K; Gronwald J; Jakubowska A; Górski B; Dębniak T; Masojć B; Huzarski T; Muir KR; Lophatananon A; Lubiński J; Narod SA;
Br J Cancer; 2013 Jun; 108(12):2601-9. PubMed ID: 23722471
[TBL] [Abstract][Full Text] [Related]
2. An inherited NBN mutation is associated with poor prognosis prostate cancer.
Cybulski C; Wokołorczyk D; Kluźniak W; Jakubowska A; Górski B; Gronwald J; Huzarski T; Kashyap A; Byrski T; Dębniak T; Gołąb A; Gliniewicz B; Sikorski A; Switała J; Borkowski T; Borkowski A; Antczak A; Wojnar L; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała P; Narod SA; Lubiński J;
Br J Cancer; 2013 Feb; 108(2):461-8. PubMed ID: 23149842
[TBL] [Abstract][Full Text] [Related]
3. A novel founder CHEK2 mutation is associated with increased prostate cancer risk.
Cybulski C; Huzarski T; Górski B; Masojć B; Mierzejewski M; Debniak T; Gliniewicz B; Matyjasik J; Złowocka E; Kurzawski G; Sikorski A; Posmyk M; Szwiec M; Czajka R; Narod SA; Lubiński J
Cancer Res; 2004 Apr; 64(8):2677-9. PubMed ID: 15087378
[TBL] [Abstract][Full Text] [Related]
4. The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome.
Lener MR; Kashyap A; Kluźniak W; Cybulski C; Soluch A; Pietrzak S; Huzarski T; Gronwald J; Lubiński J
Cancer Res Treat; 2017 Apr; 49(2):430-436. PubMed ID: 27488870
[TBL] [Abstract][Full Text] [Related]
5. Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer?
Lener MR; Scott RJ; Kluźniak W; Baszuk P; Cybulski C; Wiechowska-Kozłowska A; Huzarski T; Byrski T; Kładny J; Pietrzak S; Soluch A; Jakubowska A; Lubiński J
Int J Cancer; 2016 Aug; 139(3):601-6. PubMed ID: 27038244
[TBL] [Abstract][Full Text] [Related]
6. The presence of prostate cancer at biopsy is predicted by a number of genetic variants.
Kashyap A; Kluźniak W; Wokołorczyk D; Gołąb A; Sikorski A; Słojewski M; Gliniewicz B; Świtała J; Borkowski T; Borkowski A; Antczak A; Wojnar Ł; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała P; Piotrowski K; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Dębniak T; Górski B; Masojć B; van de Wetering T; Menkiszak J; Akbari MR; Lubiński J; Narod SA; Cybulski C;
Int J Cancer; 2014 Mar; 134(5):1139-46. PubMed ID: 24037955
[TBL] [Abstract][Full Text] [Related]
7. Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
Górski B
Hered Cancer Clin Pract; 2006 Aug; 4(3):142-52. PubMed ID: 20223018
[TBL] [Abstract][Full Text] [Related]
8. CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from Turkish population.
Bayram S; Topaktaş M; Akkız H; Bekar A; Akgöllü E
Cancer Epidemiol; 2012 Oct; 36(5):453-7. PubMed ID: 22521562
[TBL] [Abstract][Full Text] [Related]
9. Initial Findings from a High Genetic Risk Prostate Cancer Clinic.
Sessine MS; Das S; Park B; Salami SS; Kaffenberger SD; Kasputis A; Solorzano M; Luke M; Vince RA; Kaye DR; Borza T; Stoffel EM; Cobain E; Merajver SD; Jacobs MF; Milliron KJ; Caba L; van Neste L; Mondul AM; Morgan TM
Urology; 2021 Oct; 156():96-103. PubMed ID: 34280438
[TBL] [Abstract][Full Text] [Related]
10. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer.
Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; Gliniewicz B; Sikorski A; Stawicka M; Godlewski D; Kwias Z; Antczak A; Krajka K; Lauer W; Sosnowski M; Sikorska-Radek P; Bar K; Klijer R; Zdrojowy R; Małkiewicz B; Borkowski A; Borkowski T; Szwiec M; Narod SA; Lubiński J
J Med Genet; 2006 Nov; 43(11):863-6. PubMed ID: 17085682
[TBL] [Abstract][Full Text] [Related]
11. Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations.
Kaufman B; Laitman Y; Gronwald J; Winqvist R; Irmejs A; Lubinski J; Pylkäs K; Gardovskis J; Miklasevics E; Friedman E
Fam Cancer; 2009; 8(4):473-8. PubMed ID: 19609724
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of Gene Mutations and Polymorphic Variants and their Association with Prostate Cancer Risk in Polish Men.
Heise M; Jarzemski P; Nowak D; Bąk A; Junkiert-Czarnecka A; Pilarska-Deltow M; Borysiak M; Pilarska B; Haus O
Cancer Control; 2022; 29():10732748211062342. PubMed ID: 35638715
[No Abstract] [Full Text] [Related]
13. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.
Kote-Jarai Z; Mikropoulos C; Leongamornlert DA; Dadaev T; Tymrakiewicz M; Saunders EJ; Jones M; Jugurnauth-Little S; Govindasami K; Guy M; Hamdy FC; Donovan JL; Neal DE; Lane JA; Dearnaley D; Wilkinson RA; Sawyer EJ; Morgan A; Antoniou AC; Eeles RA;
Ann Oncol; 2015 Apr; 26(4):756-761. PubMed ID: 25595936
[TBL] [Abstract][Full Text] [Related]
14. Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia.
Sokolenko AP; Rozanov ME; Mitiushkina NV; Sherina NY; Iyevleva AG; Chekmariova EV; Buslov KG; Shilov ES; Togo AV; Bit-Sava EM; Voskresenskiy DA; Chagunava OL; Devilee P; Cornelisse C; Semiglazov VF; Imyanitov EN
Fam Cancer; 2007; 6(3):281-6. PubMed ID: 17333477
[TBL] [Abstract][Full Text] [Related]
15. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
16. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women.
Novak DJ; Chen LQ; Ghadirian P; Hamel N; Zhang P; Rossiny V; Cardinal G; Robidoux A; Tonin PN; Rousseau F; Narod SA; Foulkes WD
BMC Cancer; 2008 Aug; 8():239. PubMed ID: 18706089
[TBL] [Abstract][Full Text] [Related]
18. Utility of incorporating genetic variants for the early detection of prostate cancer.
Nam RK; Zhang WW; Trachtenberg J; Seth A; Klotz LH; Stanimirovic A; Punnen S; Venkateswaran V; Toi A; Loblaw DA; Sugar L; Siminovitch KA; Narod SA
Clin Cancer Res; 2009 Mar; 15(5):1787-93. PubMed ID: 19223501
[TBL] [Abstract][Full Text] [Related]
19. The digital rectal examination (DRE) remains important - outcomes from a contemporary cohort of men undergoing an initial 12-18 core prostate needle biopsy.
Palmerola R; Smith P; Elliot V; Reese CT; Mahon FB; Harpster LE; Icitovic N; Raman JD
Can J Urol; 2012 Dec; 19(6):6542-7. PubMed ID: 23228289
[TBL] [Abstract][Full Text] [Related]
20. Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.
Liss MA; Xu J; Chen H; Kader AK
Prostate; 2015 Sep; 75(12):1322-8. PubMed ID: 25982801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
